- Home
- CX vs QGEN Comparison
CX vs QGEN Comparison
Compare CX & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CX
- QGEN
- Stock Information
- Founded
- CX 1906
- QGEN 1986
- Country
- CX Mexico
- QGEN Netherlands
- Employees
- CX N/A
- QGEN N/A
- Industry
- CX Building Materials
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CX Industrials
- QGEN Health Care
- Exchange
- CX Nasdaq
- QGEN Nasdaq
- Market Cap
- CX 8.5B
- QGEN 9.5B
- IPO Year
- CX 1999
- QGEN 1996
- Fundamental
- Price
- CX $5.64
- QGEN $44.67
- Analyst Decision
- CX Buy
- QGEN Buy
- Analyst Count
- CX 6
- QGEN 9
- Target Price
- CX $7.70
- QGEN $51.42
- AVG Volume (30 Days)
- CX 10.1M
- QGEN 865.8K
- Earning Date
- CX 02-06-2025
- QGEN 02-04-2025
- Dividend Yield
- CX 0.74%
- QGEN 2.96%
- EPS Growth
- CX N/A
- QGEN N/A
- EPS
- CX 0.02
- QGEN 0.41
- Revenue
- CX $17,249,067,000.00
- QGEN $1,966,174,000.00
- Revenue This Year
- CX $5.48
- QGEN $2.78
- Revenue Next Year
- CX $3.14
- QGEN $5.69
- P/E Ratio
- CX $18.13
- QGEN $107.74
- Revenue Growth
- CX 5.20
- QGEN 0.62
- 52 Week Low
- CX $5.00
- QGEN $39.03
- 52 Week High
- CX $9.27
- QGEN $47.44
- Technical
- Relative Strength Index (RSI)
- CX 50.48
- QGEN 54.59
- Support Level
- CX $5.50
- QGEN $44.02
- Resistance Level
- CX $5.64
- QGEN $46.08
- Average True Range (ATR)
- CX 0.16
- QGEN 0.76
- MACD
- CX -0.00
- QGEN -0.03
- Stochastic Oscillator
- CX 40.82
- QGEN 41.98
About CX Cemex S.A.B. de C.V. Sponsored ADR
Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and services.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).